SCHEMBL2902613

SCHEMBL2902613

Fc1cccc(-c2ccc(C(c3c[nH]nc3-c3ccco3)N3CCOCC3)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 2/20 0.37
PIK3CA P42336 2/20 0.37
STK4 Q13043 1/20 0.37
STK3 Q13188 1/20 0.37
LRRK2 Q5S007 1/20 0.37
P4HB P07237 1/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 5/20 0.35
TP53 P04637 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
PRKDC P78527 1/20 0.33
SLC2A1 P11166 1/20 0.33
ACHE P22303 1/20 0.33
ALDH1A1 P00352 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
ATR Q13535 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL2905731 0.93 OPRD1 (0.35) PIK3R1PIK3CASTK4STK3LRRK2
SCHEMBL2903266 0.91 P4HB (0.41) PIK3R1PIK3CASTK4STK3LRRK2
SCHEMBL2903067 0.91 OPRD1 (0.37) PIK3R1PIK3CAP4HBHRH3MEN1
SCHEMBL2910374 0.87 ALDH1A1 (0.41) PIK3R1PIK3CALMNAMAPTTP53
SCHEMBL2902357 0.87 HRH3 (0.37) PIK3R1PIK3CAP4HBLMNAMAPT
SCHEMBL2905003 0.85 SIRT1 (0.38) P4HBLMNAMAPTTP53ALDH1A1
SCHEMBL2908848 0.85 LRRK2 (0.36) PIK3R1PIK3CALRRK2LMNAMAPT
SCHEMBL2908995 0.84 BRAF (0.46) P4HBLMNAMAPTTP53ALDH1A1
SCHEMBL2902824 0.83 MAPT (0.47) STK4STK3LMNAMAPTTP53
SCHEMBL2904791 0.83 CYP3A4 (0.42) LMNAALDH1A1CYP3A4KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A PIK3R1 2479/4885PIK3CA 3500/4885STK4 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.